Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Nov 2023 08:32 AM
RNS
Scancell to present at 20th SMR Congress
01 Nov 2023 07:00 AM
RNS
Scancell to present at 38th Annual SITC meeting
31 Oct 2023 12:00 PM
RNS
Notice of AGM
31 Oct 2023 07:00 AM
RNS
Results for the Year Ended 30 April 2023
20 Oct 2023 07:00 AM
RNS
Update on Final Results
18 Oct 2023 07:00 AM
RNS
Scancell to speak at World Vaccine Congress Europe
17 Oct 2023 07:00 AM
RNS
Block Listing Six Monthly Return
11 Oct 2023 07:00 AM
RNS
Change of Date for Final Results
03 Oct 2023 07:00 AM
RNS
Notice of Final Results and Investor Presentation
19 Sep 2023 07:00 AM
RNS
Positive data from Phase 2 SCOPE trial with SCIB1
14 Sep 2023 07:00 AM
RNS
Scancell to present three posters at ICI
07 Sep 2023 07:00 AM
RNS
Scancell Appoints Head of Business Development
29 Aug 2023 07:00 AM
RNS
Scancell Appoints Sath Nirmalananthan as CFO
31 Jul 2023 07:00 AM
RNS
Modi-1 trial open for expansion in CPI combination
13 Jul 2023 09:14 AM
RNS
Extension of exercise period for CEO share options
10 Jul 2023 07:00 AM
RNS
Pipeline strategy and business update
02 Jun 2023 07:00 AM
RNS
Scancell to Present Modi-1 Data at ASCO
21 Apr 2023 07:00 AM
RNS
Issue of share options to Non-Executive Directors
21 Apr 2023 07:00 AM
RNS
Issue of share options to Non-Executive Directors
18 Apr 2023 07:00 AM
RNS
ModiFY Phase 1/2 poster presentation at AACR 2023
17 Apr 2023 07:00 AM
RNS
Block Listing Application to AIM
13 Mar 2023 07:00 AM
RNS
Statement re: Silicon Valley Bank (SVB)
21 Feb 2023 09:05 AM
RNS
Second Price Monitoring Extn
21 Feb 2023 09:00 AM
RNS
Price Monitoring Extension
21 Feb 2023 07:00 AM
RNS
Encouraging early efficacy data from ModiFY trial
13 Feb 2023 07:00 AM
RNS
Positive response in COVIDITY trial
08 Feb 2023 07:00 AM
RNS
Issue of Equity
01 Feb 2023 07:00 AM
RNS
Dr Jean-Michel Cosséry appointed as Chairman
25 Jan 2023 07:00 AM
RNS
Interim Results
18 Jan 2023 07:00 AM
RNS
Notice of Interim Results
06 Dec 2022 04:40 PM
RNS
Second Price Monitoring Extn
06 Dec 2022 04:35 PM
RNS
Price Monitoring Extension
21 Nov 2022 03:18 PM
RNS
Result of Annual General Meeting
07 Nov 2022 07:00 AM
RNS
Licenses Vaccitech technology to advance Modi-2
31 Oct 2022 07:00 AM
RNS
First patient dosed in expansion phase of ModiFY
28 Oct 2022 03:00 PM
RNS
Notice of AGM
28 Oct 2022 07:00 AM
RNS
Results for the year ended 30 April 2022
26 Oct 2022 07:00 AM
RNS
Directorate Changes
25 Oct 2022 04:42 PM
RNS
Second Price Monitoring Extn
25 Oct 2022 04:37 PM
RNS
Price Monitoring Extension
25 Oct 2022 02:05 PM
RNS
Second Price Monitoring Extn
25 Oct 2022 02:00 PM
RNS
Price Monitoring Extension
25 Oct 2022 11:05 AM
RNS
Second Price Monitoring Extn
25 Oct 2022 11:00 AM
RNS
Price Monitoring Extension
25 Oct 2022 07:00 AM
RNS
Signs Commercial License Agreement with Genmab
13 Oct 2022 07:00 AM
RNS
Change of Nominated Adviser
28 Sep 2022 12:31 PM
RNS
Holding(s) in Company
23 Sep 2022 07:00 AM
RNS
Preclinical data at the EuroMAbNet Annual Meeting
06 Sep 2022 12:54 PM
RNS
Change of Registered Office
16 Aug 2022 02:00 PM
RNS
First patient dosed in Cohort 2 of the ModiFY

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings